triptophenolide profile

triptophenolide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	173273
CHEMBL ID	3039217
CHEBI ID	114185
SCHEMBL ID	19236270
MeSH ID	M0107664

Synonym
BRD-K73210450-001-02-3
DIVK1C_006662
SDCCGMLS-0066775.P001
SPECTRUM_001722
SPECTRUM4_001660
SPECTRUM5_000539
triptophenolide
BSPBIO_003528
KBIOSS_002202
KBIO2_002202
KBIO2_004770
KBIO1_001606
KBIOGR_002159
KBIO2_007338
KBIO3_002756
SPECPLUS_000566
SPBIO_001655
SPECTRUM2_001618
SPECTRUM3_001928
SPECTRUM1504005
CHEBI:114185
6-hydroxy-7-isopropyl-9b-methyl-3,3b,4,5,10,11-hexahydronaphtho[2,1-e]isobenzofuran-1-one
A838080
74285-86-2
(3br,9bs)-6-hydroxy-9b-methyl-7-propan-2-yl-3,3b,4,5,10,11-hexahydronaphtho[2,1-e][2]benzofuran-1-one
CHEMBL3039217
phenanthro(1,2-c)furan-1(3h)-one, 3b,4,5,9b,10,11-hexahydro-6-hydroxy-9b-methyl-7-(1-methylethyl)-, (3br-trans)-
tryptophenolide
S9045
CCG-38739
AKOS015897179
CS-3764
AC-34444
HY-N0475
(3br,9bs)-6-hydroxy-9b-methyl-7-propan-2-yl-3,3b,4,5,10,11-hexahydronaphtho[2,1-e]isobenzofuran-1-one
Q27195253
(-)-triptophenolide
SR-05000002569-1
sr-05000002569
bdbm50199857
SCHEMBL19236270
BCP26008
mfcd00210567
DTXSID80995809
6-hydroxy-9b-methyl-7-(propan-2-yl)-3b,4,5,9b,10,11-hexahydrophenanthro[1,2-c]furan-1(3h)-one
(+)-triptophenolide
hypolide
hypolide;(+)-triptophenolide
BRD-K73210450-001-03-1
phenanthro[1,2-c]furan-1(3h)-one,3b,4,5,9b,10,11-hexahydro-6-hydroxy-9b-methyl-7-(1-methylethyl)-,(3br,9bs)-
MS-24563

Excerpt	Reference	Relevance
"Triptophenolide, C20H24O3, has been assigned two isomeric structures. "	( [The crystal structure of triptophenolide revisited]. Chen, YZ; Deng, FX; Huang, XY; Wu, QJ, 1992)	2.03

Excerpt	Relevance	Reference
" It is very important to develop a new dosage form of high effect and low toxicity by making use of advanced technology according to its characteristics."	( [Progress in research on triptolide]. Dong, J; Liu, MX; Xu, HB; Yang, XL; Yang, YJ, 2005)	0.33

Class	Description
oxo steroid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Androgen receptor	Homo sapiens (human)	IC50 (µMol)	0.3760	0.0000	0.8753	10.0000	AID1324623; AID1324624; AID1324637
Androgen receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.4670	0.0010	1.9794	14.1600	AID1324630
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
negative regulation of transcription by RNA polymerase II	Androgen receptor	Homo sapiens (human)
MAPK cascade	Androgen receptor	Homo sapiens (human)
in utero embryonic development	Androgen receptor	Homo sapiens (human)
regulation of systemic arterial blood pressure	Androgen receptor	Homo sapiens (human)
epithelial cell morphogenesis	Androgen receptor	Homo sapiens (human)
transcription by RNA polymerase II	Androgen receptor	Homo sapiens (human)
signal transduction	Androgen receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Androgen receptor	Homo sapiens (human)
cell-cell signaling	Androgen receptor	Homo sapiens (human)
spermatogenesis	Androgen receptor	Homo sapiens (human)
single fertilization	Androgen receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Androgen receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Androgen receptor	Homo sapiens (human)
positive regulation of gene expression	Androgen receptor	Homo sapiens (human)
male somatic sex determination	Androgen receptor	Homo sapiens (human)
intracellular estrogen receptor signaling pathway	Androgen receptor	Homo sapiens (human)
androgen receptor signaling pathway	Androgen receptor	Homo sapiens (human)
intracellular receptor signaling pathway	Androgen receptor	Homo sapiens (human)
positive regulation of intracellular estrogen receptor signaling pathway	Androgen receptor	Homo sapiens (human)
Leydig cell differentiation	Androgen receptor	Homo sapiens (human)
multicellular organism growth	Androgen receptor	Homo sapiens (human)
positive regulation of phosphorylation	Androgen receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Androgen receptor	Homo sapiens (human)
positive regulation of insulin-like growth factor receptor signaling pathway	Androgen receptor	Homo sapiens (human)
positive regulation of cell differentiation	Androgen receptor	Homo sapiens (human)
negative regulation of integrin biosynthetic process	Androgen receptor	Homo sapiens (human)
positive regulation of integrin biosynthetic process	Androgen receptor	Homo sapiens (human)
positive regulation of DNA-templated transcription	Androgen receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Androgen receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase III	Androgen receptor	Homo sapiens (human)
insulin-like growth factor receptor signaling pathway	Androgen receptor	Homo sapiens (human)
regulation of developmental growth	Androgen receptor	Homo sapiens (human)
animal organ formation	Androgen receptor	Homo sapiens (human)
male genitalia morphogenesis	Androgen receptor	Homo sapiens (human)
epithelial cell proliferation	Androgen receptor	Homo sapiens (human)
negative regulation of epithelial cell proliferation	Androgen receptor	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Androgen receptor	Homo sapiens (human)
activation of prostate induction by androgen receptor signaling pathway	Androgen receptor	Homo sapiens (human)
morphogenesis of an epithelial fold	Androgen receptor	Homo sapiens (human)
lateral sprouting involved in mammary gland duct morphogenesis	Androgen receptor	Homo sapiens (human)
prostate gland growth	Androgen receptor	Homo sapiens (human)
prostate gland epithelium morphogenesis	Androgen receptor	Homo sapiens (human)
epithelial cell differentiation involved in prostate gland development	Androgen receptor	Homo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesis	Androgen receptor	Homo sapiens (human)
mammary gland alveolus development	Androgen receptor	Homo sapiens (human)
positive regulation of epithelial cell proliferation involved in prostate gland development	Androgen receptor	Homo sapiens (human)
cellular response to steroid hormone stimulus	Androgen receptor	Homo sapiens (human)
cellular response to estrogen stimulus	Androgen receptor	Homo sapiens (human)
cellular response to testosterone stimulus	Androgen receptor	Homo sapiens (human)
seminiferous tubule development	Androgen receptor	Homo sapiens (human)
non-membrane-bounded organelle assembly	Androgen receptor	Homo sapiens (human)
positive regulation of miRNA transcription	Androgen receptor	Homo sapiens (human)
regulation of protein localization to plasma membrane	Androgen receptor	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway	Androgen receptor	Homo sapiens (human)
male gonad development	Androgen receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Androgen receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
transcription cis-regulatory region binding	Androgen receptor	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Androgen receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Androgen receptor	Homo sapiens (human)
RNA polymerase II general transcription initiation factor binding	Androgen receptor	Homo sapiens (human)
transcription coactivator binding	Androgen receptor	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Androgen receptor	Homo sapiens (human)
chromatin binding	Androgen receptor	Homo sapiens (human)
DNA-binding transcription factor activity	Androgen receptor	Homo sapiens (human)
nuclear receptor activity	Androgen receptor	Homo sapiens (human)
G protein-coupled receptor activity	Androgen receptor	Homo sapiens (human)
signaling receptor binding	Androgen receptor	Homo sapiens (human)
steroid binding	Androgen receptor	Homo sapiens (human)
androgen binding	Androgen receptor	Homo sapiens (human)
protein binding	Androgen receptor	Homo sapiens (human)
beta-catenin binding	Androgen receptor	Homo sapiens (human)
zinc ion binding	Androgen receptor	Homo sapiens (human)
enzyme binding	Androgen receptor	Homo sapiens (human)
ATPase binding	Androgen receptor	Homo sapiens (human)
molecular adaptor activity	Androgen receptor	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Androgen receptor	Homo sapiens (human)
POU domain binding	Androgen receptor	Homo sapiens (human)
molecular condensate scaffold activity	Androgen receptor	Homo sapiens (human)
estrogen response element binding	Androgen receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Androgen receptor	Homo sapiens (human)
nucleus	Androgen receptor	Homo sapiens (human)
nucleoplasm	Androgen receptor	Homo sapiens (human)
cytoplasm	Androgen receptor	Homo sapiens (human)
cytosol	Androgen receptor	Homo sapiens (human)
nuclear speck	Androgen receptor	Homo sapiens (human)
chromatin	Androgen receptor	Homo sapiens (human)
protein-containing complex	Androgen receptor	Homo sapiens (human)
nucleus	Androgen receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (35)

Assay ID	Title	Year	Journal	Article
AID1324620	Agonist activity at wild type AR in human PC3 cells assessed as receptor transcriptional activation at 50 to 5000 nM after 24 hrs in absence of DHT by PSA-luciferase reporter gene assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Identification of Triptophenolide from
AID1324625	Antagonist activity at AR W741C/T877A double mutant (unknown origin) transfected in human PC3 cells assessed as inhibition of DHT-induced receptor transcriptional activation after 24 hrs by PSA-luciferase reporter gene assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Identification of Triptophenolide from
AID1434297	Cytotoxic activity against human SKOV3 cells assessed as reduction in cell viability after 72 hrs by SRB assay	2017	Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3	Identification of a diverse synthetic abietane diterpenoid library for anticancer activity.
AID1368174	Antibacterial activity against Staphylococcus aureus measured after 24 hrs	2017	Bioorganic & medicinal chemistry letters, 12-15, Volume: 27, Issue:24	Identification of a diverse synthetic abietane diterpenoid library and insight into the structure-activity relationships for antibacterial activity.
AID1324626	Antagonist activity at AR in human LNCAP cells assessed as downregulation of PSA mRNA levels at 500 nM after 24 hrs in presence of DHT by RT-PCR analysis	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Identification of Triptophenolide from
AID1324622	Agonist activity at AR W741C/T877A double mutant (unknown origin) transfected in human PC3 cells assessed as receptor transcriptional activation at 50 to 5000 nM after 24 hrs in absence of DHT by PSA-luciferase reporter gene assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Identification of Triptophenolide from
AID1368176	Antibacterial activity against Escherichia coli measured after 24 hrs	2017	Bioorganic & medicinal chemistry letters, 12-15, Volume: 27, Issue:24	Identification of a diverse synthetic abietane diterpenoid library and insight into the structure-activity relationships for antibacterial activity.
AID1324623	Antagonist activity at wild type AR in human PC3 cells assessed as suppression of DHT-induced receptor transcriptional activation after 24 hrs by PSA-luciferase reporter gene assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Identification of Triptophenolide from
AID1368177	Antibacterial activity against Pseudomonas fluorescens measured after 24 hrs	2017	Bioorganic & medicinal chemistry letters, 12-15, Volume: 27, Issue:24	Identification of a diverse synthetic abietane diterpenoid library and insight into the structure-activity relationships for antibacterial activity.
AID1324637	Antagonist activity at AR F876L mutant (unknown origin) expressed in human PC3 cells assessed as inhibition of DHT-induced receptor transactivation after 24 hrs by PSA-luciferase reporter gene assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Identification of Triptophenolide from
AID1298751	Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay	2016	Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12	Kaurane and abietane diterpenoids from the roots of Tripterygium wilfordii and their cytotoxic evaluation.
AID1298755	Cytotoxicity against human A549 cells after 48 hrs by MTT assay	2016	Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12	Kaurane and abietane diterpenoids from the roots of Tripterygium wilfordii and their cytotoxic evaluation.
AID1298750	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	2016	Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12	Kaurane and abietane diterpenoids from the roots of Tripterygium wilfordii and their cytotoxic evaluation.
AID1434295	Cytotoxic activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay	2017	Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3	Identification of a diverse synthetic abietane diterpenoid library for anticancer activity.
AID1324621	Agonist activity at AR T877A mutant (unknown origin) transfected in human PC3 cells assessed as receptor transcriptional activation at 50 to 5000 nM after 24 hrs in absence of DHT by PSA-luciferase reporter gene assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Identification of Triptophenolide from
AID1324630	Displacement of fluormone-DHT green from His/GST-tagged rat AR ligand binding domain after 4 to 8 hrs by fluorescence polarization assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Identification of Triptophenolide from
AID1324624	Antagonist activity at AR T877A mutant (unknown origin) transfected in human PC3 cells assessed as inhibition of DHT-induced receptor transcriptional activation after 24 hrs by PSA-luciferase reporter gene assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Identification of Triptophenolide from
AID1324629	Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 72 hrs by MTT assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Identification of Triptophenolide from
AID1298753	Cytotoxicity against human U251 cells after 48 hrs by MTT assay	2016	Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12	Kaurane and abietane diterpenoids from the roots of Tripterygium wilfordii and their cytotoxic evaluation.
AID1324628	Cytotoxicity against human LNCAP cells assessed as cell growth inhibition after 72 hrs by MTT assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Identification of Triptophenolide from
AID1298754	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	2016	Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12	Kaurane and abietane diterpenoids from the roots of Tripterygium wilfordii and their cytotoxic evaluation.
AID1368175	Antibacterial activity against Bacillus subtilis measured after 24 hrs	2017	Bioorganic & medicinal chemistry letters, 12-15, Volume: 27, Issue:24	Identification of a diverse synthetic abietane diterpenoid library and insight into the structure-activity relationships for antibacterial activity.
AID1324634	Agonist activity at AR F876L mutant (unknown origin) expressed in human PC3 cells assessed as receptor transcriptional activation at 50 to 5000 nM after 24 hrs in absence of DHT by PSA-luciferase reporter gene assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Identification of Triptophenolide from
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1324616	Antagonist activity at AR F876L mutant (unknown origin) transfected in human PC3 cells assessed as suppression of DHT-induced receptor transcriptional activity at 500 nM after 24 hrs by PSA-luciferase reporter gene assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Identification of Triptophenolide from
AID1324617	Antagonist activity at AR in human LNCAP cells assessed as suppression of DHT-induced receptor transcriptional activity at 5 uM after 24 hrs by dual luciferase reporter gene assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Identification of Triptophenolide from
AID1298752	Cytotoxicity against human Bcap37 cells after 48 hrs by MTT assay	2016	Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12	Kaurane and abietane diterpenoids from the roots of Tripterygium wilfordii and their cytotoxic evaluation.
AID1434299	Cytotoxic activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by SRB assay	2017	Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3	Identification of a diverse synthetic abietane diterpenoid library for anticancer activity.
AID1324618	Antagonist activity at AR in human LNCAP cells assessed as suppression of DHT-induced receptor transcriptional activity at 500 nM after 24 hrs by dual luciferase reporter gene assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Identification of Triptophenolide from
AID1324631	Antagonist activity at AR in human LNCAP cells assessed as downregulation of AR protein expression after 24 hrs by Western blot analysis	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Identification of Triptophenolide from
AID1324632	Inhibition of DHT-induced AR nuclear translocation in human LNCAP cells assessed as reduction in ratio of nuclear to cytoplasmic AR levels at 5 uM after 24 hrs by DAPI-staining based confocal microscopic analysis relative DHT	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Identification of Triptophenolide from
AID1324627	Antagonist activity at AR in human LNCAP cells assessed as downregulation of PSA mRNA levels at 5 uM after 24 hrs in presence of DHT by RT-PCR analysis	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Identification of Triptophenolide from
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (5.88)	18.7374
1990's	3 (17.65)	18.2507
2000's	2 (11.76)	29.6817
2010's	10 (58.82)	24.3611
2020's	1 (5.88)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (11.76%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	15 (88.24%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
palmitic acid Palmitic Acid: A common saturated fatty acid found in fats and waxes including olive oil, palm oil, and body lipids.. hexadecanoic acid : A straight-chain, sixteen-carbon, saturated long-chain fatty acid.	2.06	1	long-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; Daphnia magna metabolite; EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor; plant metabolite
bicalutamide bicalutamide: approved for treatment of advanced prostate cancer. N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide : A member of the class of (trifluoromethyl)benzenes that is 4-amino-2-(trifluoromethyl)benzonitrile in which one of the amino hydrogens is substituted by a 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanoyl group.. bicalutamide : A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.	2.13	1	(trifluoromethyl)benzenes; monocarboxylic acid amide; monofluorobenzenes; nitrile; sulfone; tertiary alcohol
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	2.54	2	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
norfloxacin Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.	2.15	1	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug; DNA synthesis inhibitor; environmental contaminant; xenobiotic
stearic acid octadecanoic acid : A C18 straight-chain saturated fatty acid component of many animal and vegetable lipids. As well as in the diet, it is used in hardening soaps, softening plastics and in making cosmetics, candles and plastics.	2.06	1	long-chain fatty acid; saturated fatty acid; straight-chain saturated fatty acid	algal metabolite; Daphnia magna metabolite; human metabolite; plant metabolite
oleanolic acid [no description available]	2.06	1	hydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite
abietic acid abietic acid : An abietane diterpenoid that is abieta-7,13-diene substituted by a carboxy group at position 18.	2.55	2	abietane diterpenoid; monocarboxylic acid	plant metabolite
tricosanoic acid tricosanoic acid : A very long-chain fatty acid that is tricosane in which one of the methyl groups has been oxidised to the corresponding carboxylic acid.	2.06	1	straight-chain saturated fatty acid; very long-chain fatty acid	Daphnia magna metabolite; human metabolite; plant metabolite
glucose, (beta-d)-isomer beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.	2.21	1	D-glucopyranose	epitope; mouse metabolite
triptonide triptonide: extracted from Tripterygium wilfordii; structure given in first source. triptonide : A diterpene triepoxide that is triptobenzene K in which the acylhydroquinone moiety has undergone oxidation to the corresponding triepoxyketone derivative. It has been isolated from the roots of Tripterygium wilfordii.	7.78	3	butenolide; cyclic ketone; diterpene triepoxide; organic heteroheptacyclic compound	anti-inflammatory agent; antineoplastic agent; immunosuppressive agent
friedelin 3-friedelanone: from the stem bark of Irvingia gabonensis; structure in first source. friedelin : A pentacyclic triterpenoid that is perhydropicene which is substituted by an oxo group at position 3 and by methyl groups at the 4, 4a, 6b, 8a, 11, 11, 12b, and 14a-positions (the 4R,4aS,6aS,6bR,8aR,12aR,12bS,14aS,14bS-enantiomer). It is the major triterpenoid constituent of cork.	2.06	1	cyclic terpene ketone; pentacyclic triterpenoid	anti-inflammatory drug; antipyretic; non-narcotic analgesic; plant metabolite
hydroxyflutamide [no description available]	2.13	1
dehydroabietic acid dehydroabietic acid: major aquatic toxicant in effluent of pulp and paper mills. dehydroabietic acid : An abietane diterpenoid that is abieta-8,11,13-triene substituted at position 18 by a carboxy group.. dehydroabietate : A monocarboxylic acid anion that is the conjugate base of dehydroabietic acid, obtained by deprotonation of the carboxy group.	2.55	2	abietane diterpenoid; carbotricyclic compound; monocarboxylic acid	allergen; metabolite
triptolide [no description available]	9.43	6	diterpenoid; epoxide; gamma-lactam; organic heteroheptacyclic compound	antispermatogenic agent; plant metabolite
celastrol [no description available]	2.53	2	monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory drug; antineoplastic agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Hsp90 inhibitor; metabolite
wilforlide a wilforlide A: form Tripterygium regelii; Chinese medicinal plant extract	2.13	1
methyl abietate methyl abietate: RN given refers to (1R-(1alpha,4abeta,4balpha,10aalpha))-isomer	2.55	2
gamma-sitosterol clionasterol : A member of the class of phytosterols that is poriferast-5-ene carrying a beta-hydroxy substituent at position 3.	2.06	1	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; phytosterols	marine metabolite; plant metabolite
glycosides [no description available]	2.6	1
cytellin cytellin: a phytosterol preparation of mainly B-sitosterol, that was marketed by Eli Lilly to lower cholesterol 1957 to 1982	2.06	1
naloxone Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.	1.96	1	morphinane alkaloid; organic heteropentacyclic compound; tertiary alcohol	antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist
morphine Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.	1.96	1	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
demethylzeylasteral demethylzeylasteral: a phenolic nortriterpene; isolated from the root cortex of Tripterygium Wilfordii Hook f.. demethylzeylasteral : A carbopolycyclic compound with formula C29H36O6, originally isolated from Tripterygium wilfordii.	2.53	2	arenecarbaldehyde; benzenediols; carbopolycyclic compound; cyclic ketone; enone; oxo monocarboxylic acid	anti-inflammatory agent; EC 2.4.1.17 (glucuronosyltransferase) inhibitor; immunosuppressive agent; nephroprotective agent; plant metabolite
mdv 3100 [no description available]	2.13	1	(trifluoromethyl)benzenes; benzamides; imidazolidinone; monofluorobenzenes; nitrile; thiocarbonyl compound	androgen antagonist; antineoplastic agent
phenanthrenes Phenanthrenes: POLYCYCLIC AROMATIC HYDROCARBONS composed of three fused BENZENE rings.. phenanthrenes : Any benzenoid aromatic compound that consists of a phenanthrene skeleton and its substituted derivatives thereof.	3.82	3

Condition	Relationship Strength	Studies
Benign Neoplasms [description not available]	3.03	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.03	1
Anemia, Fanconi [description not available]	2.13	1
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	2.13	1
Ache [description not available]	1.96	1
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	1.96	1

triptophenolide

Description

Cross-References

Synonyms (51)

Research Excerpts

Effects

Dosage Studied

Drug Classes (1)

Protein Targets (2)

Inhibition Measurements

Biological Processes (56)

Molecular Functions (23)

Ceullar Components (8)

Bioassays (35)

Research

Studies (17)

Market Indicators

Research Demand Index: 22.23

Study Types

triptophenolide

Description

Cross-References

Synonyms (51)

Research Excerpts

Effects

Dosage Studied

Drug Classes (1)

Protein Targets (2)

Inhibition Measurements

Biological Processes (56)

Molecular Functions (23)

Ceullar Components (8)

Bioassays (35)

Research

Studies (17)

Market Indicators

Research Demand Index: 22.23

Study Types

Related Drugs (25)

Related Conditions (6)